XBP1 and breast cancer: Collectively, our findings reveal a crucial role for the spliced XBP1-miR-378 pathway in ER-positive breast cancer and suggest that XBP1s may contribute to the development of endocrine-resistant breast cancer, in part, by downregulating the expression of miR-378.